Labcorp Holdings Inc. Share Price

Equities

LH

US5049221055

Healthcare Facilities & Services

Market Closed - Nyse 21:00:02 14/06/2024 BST 5-day change 1st Jan Change
199.9 USD +1.73% Intraday chart for Labcorp Holdings Inc. +1.67% -12.06%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 12.81B 1,011B Sales 2025 * 13.41B 1,059B Capitalization 16.85B 1,330B
Net income 2024 * 955M 75.4B Net income 2025 * 1.09B 86.21B EV / Sales 2024 * 1.68 x
Net Debt 2024 * 4.73B 373B Net Debt 2025 * 4.23B 334B EV / Sales 2025 * 1.57 x
P/E ratio 2024 *
17.6 x
P/E ratio 2025 *
15.3 x
Employees 61,975
Yield 2024 *
1.47%
Yield 2025 *
1.5%
Free-Float 99.65%
More Fundamentals * Assessed data
Dynamic Chart
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $258 From $256 MT
HSBC Adjusts Price Target on Laboratory Corp of America Holdings to $210 From $225, Keeps Hold Rating MT
Transcript : Labcorp Holdings Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 02:00 PM
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio CI
JPMorgan Adjusts Price Target on Laboratory Corp of America Holdings to $243 From $261 MT
Some of the biggest splits in Corporate America RE
Declaration of Voting Results by Laboratory Corporation of America Holdings CI
Declaration of Voting Results by Laboratory Corporation of America Holdings CI
Declaration of Voting Results by Laboratory Corporation of America Holding CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing MT
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating MT
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy CI
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal CI
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021. CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244 MT
More news
1 day+1.73%
1 week+1.67%
Current month+2.55%
1 month-6.22%
3 months-4.46%
6 months-8.94%
Current year-12.06%
More quotes
1 week
192.38
Extreme 192.38
200.10
1 month
191.97
Extreme 191.97
214.14
Current year
191.97
Extreme 191.97
234.09
1 year
191.97
Extreme 191.97
243.30
3 years
191.97
Extreme 191.97
317.17
5 years
98.02
Extreme 98.02
317.17
10 years
95.61
Extreme 95.61
317.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 31/03/13
Director of Finance/CFO 62 15/06/14
Compliance Officer 65 31/01/19
Members of the board TitleAgeSince
Chief Executive Officer 59 31/03/13
Director/Board Member 68 31/12/12
Director/Board Member 66 16/05/06
More insiders
Date Price Change Volume
14/06/24 199.9 +1.73% 716,109
13/06/24 196.5 +0.06% 632,442
12/06/24 196.4 -0.54% 626,340
11/06/24 197.4 +0.77% 464,887
10/06/24 195.9 -0.35% 514,959

Delayed Quote Nyse, June 14, 2024 at 09:00 pm

More quotes
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
199.9 USD
Average target price
237.6 USD
Spread / Average Target
+18.87%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW